Health Care & Life Sciences » Pharmaceuticals | Elite Pharmaceuticals Inc.

Elite Pharmaceuticals Inc. | Income Statement

Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
4,601.40
5,015.20
12,498.30
9,637.70
7,458.70
7,568.50
Cost of Goods Sold (COGS) incl. D&A
3,737.00
3,630.60
5,149.80
6,250.80
4,311.60
5,907.50
Gross Income
864.40
1,384.70
7,348.50
3,386.90
3,147.10
1,661
SG&A Expense
6,148.00
17,891.60
15,665.30
10,742.90
12,198.40
10,819.70
EBIT
-
-
-
7,355.90
9,051.30
9,158.70
Unusual Expense
35,389.80
20,340.90
7,394.00
9,525.10
4,650.30
180
Non Operating Income/Expense
60.40
1,670.70
-
-
-
629
Interest Expense
859.30
287.20
280.70
238.20
335.50
369.20
Pretax Income
41,553.50
5,217.40
1,203.50
1,943.60
4,719.00
9,955.30
Income Tax
292.60
3.20
520.50
1,867.60
1,045.80
676
Consolidated Net Income
96,575.30
28,929.70
9,968.70
24,525.50
3,673.20
9,279.30
Net Income
96,575.30
28,929.70
9,968.70
24,525.50
3,673.20
9,279.30
Net Income After Extraordinaries
96,575.30
28,929.70
9,968.70
24,525.50
3,673.20
9,279.30
Net Income Available to Common
96,575.30
28,929.70
9,968.70
24,525.50
3,673.20
9,279.30
EPS (Basic)
0.21
0.04
0.01
0.01
0.01
0.01
Basic Shares Outstanding
463,022.00
591,215.00
673,905.50
838,665.80
796,069.40
814,172.90
EPS (Diluted)
0.21
0.04
0.01
0.01
0.01
0.01
Diluted Shares Outstanding
463,022.00
757,579.20
673,905.50
844,506.20
798,169.40
816,313
EBITDA
4,782.70
15,890.00
7,651.20
6,655.60
8,069.10
7,916
Non-Operating Interest Income
-
-
-
12.60
17.50
21.50
Other After Tax Income (Expense)
55,314.40
23,709.10
9,285.70
20,714.30
-
-

About Elite Pharmaceuticals

View Profile
Address
165 Ludlow Avenue
Northvale New Jersey 07647
United States
Employees -
Website http://www.elitepharma.com
Updated 07/08/2019
Elite Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology, as it relates to abuse resistant products. Its strategy includes off-patent drug products for life cycle management and developing generic versions of controlled-release drug products. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.